PA-SYNERGIS-SOFTWARE
30.3.2022 14:23:11 CEST | Business Wire | Press release
Synergis Software, a global leader in engineering document management and workflow solutions, is hosting a free live panel for engineering, operations, and IT leaders who want to learn how to overcome drawing management and collaboration chaos and create a more resilient, adaptable, and secure utility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005277/en/
The live 90-minute webinar will take place on Wednesday, April 6, 2022, at 2:00 p.m. EDT. The panel will be moderated by Scott Lamond, Vice President at Synergis Software with these guest panelists:
- Paul J. Melzen, P.E., Director, Eversource Substation Engineering & Design
- Blake Donley, Principal Systems Analyst, Great River Energy
- Bernie Voges, Senior Protection Engineer, Hoosier Energy
Discussion topics will include the advantages of a centralized platform for drawing management and collaboration, best practices, and lessons learned for implementation and user adoption. Attendees will gain insights that will help them:
- Align engineering, construction, field service, and operations
- Ensure fast access to the right version, day or night
- Eliminate expensive mistakes and outages
- Simplify collaboration and accelerate projects
- Capture tribal knowledge and secure digital assets
- Streamline compliance and drive standards
The live Q&A session will allow attendees to get their questions answered.
Register now to reserve your seat, and if you can't attend, register to receive a replay.
“Our utility customers know the hidden costs and inefficiencies of doing business without a centralized drawing management and collaboration solution that aligns engineering, field service, operations, and construction,” says Scott Lamond, vice president at Synergis Software. “With our Adept engineering document management solution, utilities will increase asset reliability, improve operational efficiency, reduce compliance and safety risk, and lower operating costs.”
Paul Melzen, director, Eversource substation engineering and design says, “In addition to configuration control, drawing management has become more and more critical to reliability and compliance. If the drawings don't represent what's in the field, it's just a human error trap."
“When the people in the field can’t find the correct drawing, it can result in more man-hours spent to resolve an issue, which can have a direct impact on our customers,” adds Melzen. “Moreover, if we're designing and bidding on a project using inaccurate drawings, we’re exposing ourselves to the risk of change orders from our engineering and construction contractors. Not only can these issues have significant cost impacts to the company, but they can also impact compliance, reliability and safety.”
Synergis Adept is a proven solution used by utility customers such as Con Edison, Northwestern Energy, San Diego Gas & Electric, Dominion Energy, Emera Companies, Lansing Board of Water and Light, California Water Authority, Platte River Authority, Turlock Irrigation District and more .
For further information on the webinar or to register, visit the event page event page. If you can't attend, register to receive the replay.
About Synergis Software
Synergis Software is a global leader in document management and workflow solutions and is the creator of Synergis Adept software. Adept serves more than 120,000 users across dozens of industries providing fast, centralized access to design and business documents in a secure, collaborative environment. Adept Integrator connects your enterprise applications so your data and business processes flow seamlessly across your entire IT infrastructure.
Named the customer service leader in the global engineering information management market by Frost & Sullivan and ranked in the Top 5 globally by Helpdesk International for three consecutive years, our commitment to clients is unwavering.
Founded in 1985, Synergis Technologies, LLC is headquartered in Bucks County, PA and is privately owned and funded.
About Eversource
Eversource (NYSE: ES), celebrated as a national leader for its corporate citizenship, is the #1 energy company in Newsweek’s list of America’s Most Responsible Companies for 2021 and recognized as one of America’s Most JUST Companies. The #1 energy efficiency provider in the nation, the company is empowering a clean energy future in the Northeast, with nationally recognized energy efficiency solutions and successful programs to integrate new clean energy resources like solar, offshore wind, electric vehicles, and battery storage, into the electric system.
About Great River Energy
Great River Energy (GRE) is wholesale power cooperative; our member-owners are 28 Minnesota electric distribution cooperatives. Individuals and businesses are members of those distribution cooperatives based on their geographic location.
As a Touchstone Energy Cooperative, GRE is a part of a nationwide alliance made of more than 750 electric cooperatives in 46 states.
About Hoosier Energy
Hoosier Energy serves 18-member electric cooperatives in central and southern Indiana and southeastern Illinois. Founded in 1949 and based in Bloomington, Indiana, Hoosier Energy is a generation and transmission electric cooperative providing wholesale power and services to member distribution cooperatives. Their portfolio includes coal, natural gas and renewable energy resources that deliver power through a nearly 1,700-mile transmission network.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005277/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
